Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Sun Joo Cha, Kiyoung Kim
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	MDPI AG 2022-01-01
Sraith:	Antioxidants
Ábhair:	edaravone oxidative stress antioxidant mitochondria neurodegenerative disease amyotrophic lateral sclerosis
Rochtain ar líne:	https://www.mdpi.com/2076-3921/11/2/195

Míreanna comhchosúla

A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
de réir: Erdi Şahin
Foilsithe / Cruthaithe: (2018-03-01)

Edaravone: A new hope for patients with amyotrophic lateral sclerosis
de réir: Shivangi Garg, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
de réir: Hideki Houzen, et al.
Foilsithe / Cruthaithe: (2021-07-01)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
de réir: Jin-Mo Park, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
de réir: Chang Liu, et al.
Foilsithe / Cruthaithe: (2024-10-01)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
de réir: Hee Jo Han, et al.
Foilsithe / Cruthaithe: (2022-12-01)

New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments
de réir: Maria A. Lapshina, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Bulbar Onset Amyotrophic Lateral Sclerosis: A Case Report
de réir: Kabindra Rai, et al.
Foilsithe / Cruthaithe: (2023-02-01)

The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
de réir: Jiantao Zhao, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Recent Advances on the Role of GSK3β in the Pathogenesis of Amyotrophic Lateral Sclerosis
de réir: Hyun-Jun Choi, et al.
Foilsithe / Cruthaithe: (2020-09-01)

Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
de réir: Benjamin Rix Brooks, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Iranian clinical practice guideline for amyotrophic lateral sclerosis
de réir: Reza Boostani, et al.
Foilsithe / Cruthaithe: (2023-06-01)

Amyotrophic lateral sclerosis – aetiology, diagnostics and multidirectional, team, long-term care
de réir: Kamila Tuzim, et al.
Foilsithe / Cruthaithe: (2018-08-01)

Amyotrophic lateral sclerosis – aetiology, diagnostics and multidirectional, team, long-term care
de réir: Kamila Tuzim, et al.
Foilsithe / Cruthaithe: (2018-08-01)

The Protective Effect of Edaravone on TDP-43 Plus Oxidative Stress-Induced Neurotoxicity in Neuronal Cells: Analysis of Its Neuroprotective Mechanisms Using RNA Sequencing
de réir: Aki Soejima-Kusunoki, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Amyotrophic lateral sclerosis with frontotemporal dementia
de réir: Corina Roman-Filip, et al.
Foilsithe / Cruthaithe: (2010-09-01)

Synthesis and Characterization of Edaravone Analogues as Remyelinating Agents and Putative Mechanistic Probes
de réir: Eleonora Colombo, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Advancements and challenges in amyotrophic lateral sclerosis
de réir: David Bradford, et al.
Foilsithe / Cruthaithe: (2024-05-01)

Intestinal Microbiota and Sclerosis Lateral Amyotrophic
de réir: Mariana Dantas de Carvalho Vilar, et al.
Foilsithe / Cruthaithe: (2022-03-01)

The implications of DNA methylation for amyotrophic lateral sclerosis
de réir: ADRIANA HELENA DE OLIVEIRA REIS, et al.
Foilsithe / Cruthaithe: (2023-10-01)

The role of statins in amyotrophic lateral sclerosis: protective or not?
de réir: Hayder M. Al-kuraishy, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Evaluation of Sensory Nerve Conduction Abnormalities in Patients with Amyotrophic Lateral Sclerosis
de réir: Waseem H. Alkhaffaf
Foilsithe / Cruthaithe: (2021-06-01)

New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis
de réir: Frances Theunissen, et al.
Foilsithe / Cruthaithe: (2021-11-01)

Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704
de réir: Dong Wook Kang, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Prevalence of amyotrophic lateral sclerosis in Latium region, Italy
de réir: Maria Puopolo, et al.
Foilsithe / Cruthaithe: (2021-12-01)

Mechanistic Insights of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis: An Update on a Lasting Relationship
de réir: Niccolò Candelise, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Progress in the study of mitochondrial dysfunction in pathogenesis of amyotrophic lateral sclerosis
de réir: LIU Liyang, LIU Qing, LIU Yaping, ZHANG Xue
Foilsithe / Cruthaithe: (2023-02-01)

Amyotrophic lateral sclerosis: pathogenetic mechanisms and new approaches to pharmacotherapy (literature review)
de réir: T. M. Alekseeva, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Commentary: Urinary Neopterin, a New Marker of the Neuroinflammatory Status in Amyotrophic Lateral Sclerosis
de réir: Gisele Espíndola, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Assessment of therapeutic response of edaravone and riluzole combination therapy in amyotrophic lateral sclerosis patients
de réir: Swapnil Samadhiya, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Oligodendrocytes in amyotrophic lateral sclerosis and frontotemporal dementia: the new players on stage
de réir: Marguerite Jamet, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Biomarkers of Amyotrophic Lateral Sclerosis: Current Status and Interest of Oxysterols and Phytosterols
de réir: Anne Vejux, et al.
Foilsithe / Cruthaithe: (2018-01-01)

The Cell Autonomous and Non-Cell Autonomous Aspects of Neuronal Vulnerability and Resilience in Amyotrophic Lateral Sclerosis
de réir: Christoph Schweingruber, et al.
Foilsithe / Cruthaithe: (2022-08-01)

Evaluation of Peripheral Immune Activation in Amyotrophic Lateral Sclerosis
de réir: Mengli Wang, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Depression in amyotrophic lateral sclerosis
de réir: Joanna Iłżecka
Foilsithe / Cruthaithe: (2021-10-01)

Amyotrophic lateral sclerosis : advances and perspectives of neuronanomedicine /
de réir: Machtoub, Lina, author, et al.
Foilsithe / Cruthaithe: (2016)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
de réir: HaEun Cho, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Staging model for amyotrophic lateral sclerosis in Singapore
de réir: Yuan Teck Tay, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Analysis of SOD1 and C9orf72 mutations in patients with amyotrophic lateral sclerosis in Antioquia, Colombia
de réir: Jimena Jaramillo, et al.
Foilsithe / Cruthaithe: (2022-12-01)

Pain in Amyotrophic Lateral Sclerosis Is Underrated
de réir: Soyoung Kwak, et al.
Foilsithe / Cruthaithe: (2024-12-01)